These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 23873597

  • 1. Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.
    Rabadi MH, Kreymborg K, Vincent AS.
    Drugs R D; 2013 Sep; 13(3):175-81. PubMed ID: 23873597
    [Abstract] [Full Text] [Related]

  • 2. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F203 Investigators.
    Lancet; 2009 Feb 28; 373(9665):732-8. PubMed ID: 19249634
    [Abstract] [Full Text] [Related]

  • 3. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B, Filli L, Reuter K, Kapitza S, Lörincz L, Sutter T, Weller D, Farkas M, Easthope CS, Czaplinski A, Weller M, Linnebank M.
    Mult Scler; 2016 Oct 28; 22(11):1463-1475. PubMed ID: 26762672
    [Abstract] [Full Text] [Related]

  • 4. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
    Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ.
    Clin Ther; 2015 Dec 01; 37(12):2780-7. PubMed ID: 26565077
    [Abstract] [Full Text] [Related]

  • 5. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Macdonell R, Nagels G, Laplaud DA, Pozzilli C, de Jong B, Martins da Silva A, Nicholas R, Lechner-Scott J, Gaebler JA, Agarwal S, Wang P, Yeh M, Hovenden M, Soelberg Sørensen P.
    Mult Scler; 2016 Jun 01; 22(7):944-54. PubMed ID: 26447066
    [Abstract] [Full Text] [Related]

  • 6. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
    Limone BL, Sidovar MF, Coleman CI.
    Health Qual Life Outcomes; 2013 Jun 26; 11():105. PubMed ID: 23799913
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
    Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR, MS-F203, MS-F204, and Extension Study Investigators.
    Mult Scler; 2015 Sep 26; 21(10):1322-31. PubMed ID: 25583832
    [Abstract] [Full Text] [Related]

  • 8. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
    Cameron MH, Fitzpatrick M, Overs S, Murchison C, Manning J, Whitham R.
    Mult Scler; 2014 May 26; 20(6):733-8. PubMed ID: 24099749
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
    Lugaresi A.
    Expert Opin Drug Metab Toxicol; 2015 Feb 26; 11(2):295-306. PubMed ID: 25510833
    [Abstract] [Full Text] [Related]

  • 12. Dalfampridine extended release: in multiple sclerosis.
    Chwieduk CM, Keating GM.
    CNS Drugs; 2010 Oct 26; 24(10):883-91. PubMed ID: 20839898
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
    Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A.
    J Neurol Sci; 2016 Jan 15; 360():102-9. PubMed ID: 26723984
    [Abstract] [Full Text] [Related]

  • 15. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J, ENHANCE study investigators.
    CNS Drugs; 2019 Jan 15; 33(1):61-79. PubMed ID: 30535670
    [Abstract] [Full Text] [Related]

  • 16. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI, Sobieraj DM, Marinucci LN.
    Curr Med Res Opin; 2012 Jan 15; 28(1):49-56. PubMed ID: 22073939
    [Abstract] [Full Text] [Related]

  • 17. Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    Lo AC, Ruiz JA, Koenig CM, Anderson BM, Olson KM, Triche EW.
    J Neurol Sci; 2015 Sep 15; 356(1-2):77-82. PubMed ID: 26139339
    [Abstract] [Full Text] [Related]

  • 18. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
    Fernandez O, Berger T, Hartung HP, Putzki N.
    Expert Rev Clin Pharmacol; 2012 Nov 15; 5(6):649-65. PubMed ID: 23146002
    [Abstract] [Full Text] [Related]

  • 19. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
    Mathiesen HK, Sorensen PS.
    Expert Rev Neurother; 2013 Dec 15; 13(12):1309-17. PubMed ID: 24236901
    [Abstract] [Full Text] [Related]

  • 20. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR, Bienen EJ, Blight AR.
    Clin Ther; 2012 May 15; 34(5):1056-69. PubMed ID: 22497693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.